Skip to Content
Merck
All Photos(2)

Documents

MAB4381C3

Sigma-Aldrich

Anti-TRA-1-81 Antibody, clone TRA-1-81, Cy3 conjugate

clone TRA-1-81, from mouse, CY3 conjugate

Synonym(s):

Podocalyxin, GCTM-2 antigen, Gp200, Podocalyxin-like protein 1

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

100

conjugate

CY3 conjugate

antibody form

saturated ammonium sulfate (SAS) precipitated

antibody product type

primary antibodies

clone

TRA-1-81, monoclonal

species reactivity

human

technique(s)

immunocytochemistry: suitable

isotype

IgM

NCBI accession no.

NP_001018121.1

UniProt accession no.

O00592

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... PODXL(5420)

General description

TRA-1-81 is expressed upon the surface of human teratocarcinoma stem cells (EC), human embryonic germ cells (EG) and human embryonic stem cells (ES). Both TRA-1-81 and TRA-1-60 recognize antigens that are associated with a pericellular matrix proteoglycan. TRA-1-60 reacts with a sialidase-sensitive epitope while TRA-1-81 reacts with an unknown epitope of the same molecule. TRA-1-81 is commonly used as marker of undifferentiated pluripotent human stem cells and is downregulated upon differentiation. TRA-1-81 has recently been identified as podocalyxin.

Specificity

This antibody recognizes human TRA-1-81.

Immunogen

Human embryonal carcinoma cell line 2102Ep

Application

Evaluated by Immunocytochemistry in mouse embryonic stem cells (SCR012). Immunocytochemsitry Analysis: A 1:100 dilution of this antibody did not detect TRA-1-81 in mouse embryonic stem cells (SCR012).
Research Category
Stem Cell Research
Research Sub Category
Pluripotent & Early Differentiation
This Anti-TRA-1-81 Antibody, clone TRA-1-81, Cy3 conjugate is validated for use in ICC for the detection of TRA-1-81.

Quality

Evaluated by Immunocytochemistry in H9 human embryonic stem cells.
Immunocytochemsitry Analysis: A 1:100 dilution of this antibody detected TRA-1-81 in H9 human embryonic stem cells.

Target description

420/250 kDa calculated

Physical form

Purified mouse monoclonal IgM conjugated to Cy3 in PBS with 0.1% sodium azide and 15mg/ml BSA.

Storage and Stability

Maintain refrigerated at 2-8ºC protected from light in undiluted aliquots for up to 6 months from date of receipt.

Analysis Note

Control
H9 human embryonic stem cells

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xinyu Liu et al.
Cell division, 15(1), 12-12 (2020-12-10)
Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) has opened new therapeutic possibilities. However, karyotypic abnormalities detected in iPSCs compromised their utility, especially chromosomal aberrations found at early passages raised serious safety concerns. The mechanism underlying the chromosomal abnormality
Daniel Rodrigo Marinowic et al.
Molecular medicine reports, 15(4), 2049-2056 (2017-03-06)
Focal cortical dysplasia (FCD) is caused by numerous alterations, which can be divided into abnormalities of the cortical architecture and cytological variations; however, the exact etiology of FCD remains unknown. The generation of induced pluripotent stem cells (iPSCs) from the
Christian A Di Buduo et al.
eLife, 10 (2021-06-02)
Thrombocytopenic disorders have been treated with the Thrombopoietin-receptor agonist Eltrombopag. Patients with the same apparent form of thrombocytopenia may respond differently to the treatment. We describe a miniaturized bone marrow tissue model that provides a screening bioreactor for personalized, pre-treatment

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service